A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Drug attrition rates have increased in past years, resulting in growing costs for the pharmaceutical industry and consumers. The reasons for this include the lack of in vitro models that correlate with clinical results and poor preclinical toxicity screening assays. The in vitro production of human cardiac progenitor cells and cardiomyocytes from human pluripotent stem cells provides an amenable source of cells for applications in drug discovery, disease modeling, regenerative medicine, and cardiotoxicity screening. In addition, the ability to derive human-induced pluripotent stem cells from somatic tissues, combined with current high-throughput screening and pharmacogenomics, may help realize the use of these cells to fulfill the potential of personalized medicine. In this review, we discuss the use of pluripotent stem cell-derived cardiomyocytes for drug discovery and cardiotoxicity screening, as well as current hurdles that must be overcome for wider clinical applications of this promising approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333 · cited 1×
“Over 82 million Americans suffer from some form of cardiovascular disease (CVD), accounting for nearly 27 % of the entire population [2].”
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 1×
“Current differentiation methods are designed around small-scale research paradigms [90].”
A nonviral minicircle vector for deriving human iPS cells
Jia, F., Wilson, K. D., Sun, N., Gupta, D. M., Huang, M., Li, Z., Panetta, N. J., Chen, Z. Y., Robbins, R. C., Kay, M. A., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1426 · Cited by 734
Self-citationPatient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., Navarrete, E. G., Hu, S., Wang, L., Lee, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003552 · Cited by 696 · cited 1×
“Genetic conditions that affect the heart may also be studied, including familial cardiomyopathy, familial lethal arrhythmias, and congenital heart diseases [87].”
Self-citationBurridge, P. W., Keller, G., Gold, J. D., & Wu, J. C. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.12.013 · Cited by 670
Self-citationProgress toward the clinical application of patient-specific pluripotent stem cells
Kiskinis, E., & Eggan, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40553 · Cited by 339
Assessing the Safety of Stem Cell Therapeutics
Goldring, C. E. P., Duffy, P. A., Benvenisty, N., Andrews, P. W., Ben-David, U., Eakins, R., French, N., Hanley, N. A., Kelly, L., Kitteringham, N. R., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.05.012 · Cited by 245
Lian, Q., Chow, Y., Esteban, M., Pei, D., & Tse, H.-F. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0269 · Cited by 55
Efficient Array-Based Identification of Novel Cardiac Genes through Differentiation of Mouse ESCs
Miller, R. A., Christoforou, N., Pevsner, J., McCallion, A. S., & Gearhart, J. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002176 · Cited by 35
Cited by
Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., & Stockbridge, N. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.11.004 · Cited by 540
Zhao, L., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep44735 · Cited by 375
Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000570 · Cited by 302
Self-citationTzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
“As examples, Terfenadine (trade name Seldane) was withdrawn in 1998 for inducing cardiac arrhythmias; Grepafloxacin (trade nameRaxar)waswithdrawn in 1999 for prolonging theQT interval; Rofecoxib (trade name Vioxx, Ceoxx, and Ceeoxx) was withdrawn in 2004 for the risk of myocardial infarction; and Rosiglitazone (trade…”
Self-citationEngineering of human cardiac muscle electromechanically matured to an adult-like phenotype
Ronaldson-Bouchard, K., Yeager, K., Teles, D., Chen, T., Ma, S., Song, L., Morikawa, K., Wobma, H. M., Vasciaveo, A., Ruiz, E. C., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0189-8 · Cited by 144
Metadata
- Authors
- Mordwinkin, N. M., Burridge, P. W., & Wu, J. C.
- Venue
- Journal of Cardiovascular Translational Research
- Published
- 2012-11-15
- Volume
- 6
- Issue
- 1
- Pages
- 22-30
- ISSN
- 1937-5387 (ISSN-L)
- 1937-5395
- OpenAlex
- W2091557317
- Cited by
- 128
- References
- 12
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.